Last reviewed · How we verify

NCT04889443: SHARC

Spontaneous Healing of ARticular Cartilage (SHARC)

Completed Last updated 13 March 2024
What this trial tests

trial testing Surgical cartilage repair procedure requiring harvest procedure or Autologous Stromal Cell Implantation in Cartilage Damage in 15 participants. Completed in 31 December 2023.

Timeline
1 September 2018
Primary endpoint
31 December 2023
31 December 2023

Quick facts

Lead sponsorKeele University
StatusCompleted
Study typeOBSERVATIONAL
Enrollment15
Start date1 September 2018
Primary completion31 December 2023
Estimated completion31 December 2023
Sites1 location across United Kingdom

Drugs / interventions tested

Conditions studied

Sponsor

Keele University

Who can join

18 and older, any sex, with Cartilage Damage or Cartilage Injury. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

SHARC is an observational study of cartilage patients who are treated with surgery that involves obtaining a harvest biopsy. SHARC will study the natural healing process of the harvest biopsy site based on histological and biochemical analyses of repair tissue biopsies, synovial fluid biomarkers, medical imaging (MRI) and gait analysis.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Advanced Therapy medicinal products for autologous chondrocytes and comparison of regulatory systems in target countries.
    Kim J, Park J, Song SY, Kim E. · · 2022 · cited 14× · PMID 35582708 · DOI 10.1016/j.reth.2022.04.004

Verify or expand the search:

Other recruiting trials for Cartilage Damage

Currently open trials in the same condition.

Other Keele University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04889443.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing